List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2574767/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet, The, 2013, 381, 1817-1826.	13.7	450
2	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. Journal of Clinical Oncology, 2021, 39, 1214-1222.	1.6	74
3	A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, <i>KRAS</i> Wild-Type, Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, djv258.	6.3	72
4	Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: are we contributing to malignancy?. Alimentary Pharmacology and Therapeutics, 2007, 26, 1019-1024.	3.7	71
5	Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Annals of Oncology, 2017, 28, 2511-2516.	1.2	64
6	Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, 274-281.	2.3	63
7	EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood, 2021, 137, 1468-1477.	1.4	59
8	Programmed cell death-1 inhibition in lymphoma. Lancet Oncology, The, 2015, 16, e234-e245.	10.7	56
9	CHOP versus CEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematology,the, 2018, 5, e190-e200.	4.6	50
10	Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood Reviews, 2018, 32, 400-415.	5.7	49
11	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia, 2020, 34, 2184-2197.	7.2	45
12	Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. Journal of Clinical Medicine, 2018, 7, 62.	2.4	43
13	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clinical Cancer Research, 2021, 27, 6323-6332.	7.0	42
14	Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?. Oncologist, 2012, 17, 1562-1573.	3.7	41
15	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (Râ€ <scp>CHOP</scp>) in the management of primary mediastinal Bâ€cell lymphoma: a subgroup analysis of the <scp>UK NCRI</scp> Râ€ <scp>CHOP</scp> 14 versus 21 trial. British Journal of Haematology, 2016, 175, 668-672.	2.5	38
16	Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Annals of Oncology, 2017, 28, 1540-1546.	1.2	35
17	Cardiotoxicity in Patients Treated With Bevacizumab Is Potentially Reversible. Journal of Clinical Oncology, 2011, 29, e560-e562.	1.6	31
18	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. British Journal of Haematology, 2021, 192, 1049-1053.	2.5	31

#	Article	IF	CITATIONS
19	Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. European Journal of Cancer, 2011, 47, 1146-1151.	2.8	29
20	Pembrolizumab in relapsed or refractory Richter syndrome. British Journal of Haematology, 2020, 190, e117-e120.	2.5	29
21	Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. BMC Cancer, 2012, 12, 326.	2.6	26
22	Relationship Between Colorectal Cancer Biomarkers and Response to Epidermal Growth Factor Receptor Monoclonal Antibodies. Journal of Clinical Oncology, 2010, 28, e529-e531.	1.6	23
23	Diagnosis and management of rare gastrointestinal lymphomas. Leukemia and Lymphoma, 2012, 53, 2341-2350.	1.3	23
24	Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large Bâ€cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. British Journal of Haematology, 2019, 187, 174-184.	2.5	23
25	Limited-stage diffuse large B-cell lymphoma. Blood, 2022, 139, 822-834.	1.4	22
26	Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 245-257.	2.3	20
27	Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large Bâ€cell lymphoma receiving rituximabâ€chemotherapy combinations. British Journal of Haematology, 2019, 187, 73-81.	2.5	19
28	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study. Blood, 2019, 134, 2874-2874.	1.4	19
29	The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management. Leukemia and Lymphoma, 2012, 53, 354-361.	1.3	16
30	Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Annals of Hematology, 2016, 95, 809-816.	1.8	16
31	Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 111-114.	1.5	15
32	Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab. Blood Reviews, 2017, 31, 23-35.	5.7	15
33	Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 2019, 3, 2804-2811.	5.2	15
34	Treatment of metastatic colorectal cancer: focus on panitumumab. Cancer Management and Research, 2015, 7, 189.	1.9	14
35	Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. Oncotarget, 2017, 8, 64999-65008.	1.8	14
36	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. Blood, 2021, 138, 181-181.	1.4	14

#	Article	IF	CITATIONS
37	Rechallenge with Platinum plus Fluoropyrimidine +/– Epirubicin in Patients with Oesophagogastric Cancer. Oncology, 2010, 79, 150-158.	1.9	13
38	Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013. Leukemia and Lymphoma, 2017, 58, 1805-1813.	1.3	13
39	A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Annals of Oncology, 2012, 23, 942-947.	1.2	12
40	Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (Râ€ <scp>GEM</scp> â€P) is an effective regimen in relapsed diffuse large Bâ€cell lymphoma. European Journal of Haematology, 2015, 94, 219-226.	2.2	11
41	An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma. Leukemia and Lymphoma, 2018, 59, 2749-2751.	1.3	11
42	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. Leukemia and Lymphoma, 2018, 59, 1586-1595.	1.3	10
43	Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission. British Journal of Cancer, 2018, 119, 546-550.	6.4	10
44	Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1st FLOR' Study. Blood, 2019, 134, 1523-1523.	1.4	10
45	The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. British Journal of Haematology, 2021, 195, 15-24.	2.5	9
46	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study. Blood, 2018, 132, 2969-2969.	1.4	9
47	Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study. Blood, 2020, 136, 43-44.	1.4	9
48	The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial. Blood, 2016, 128, 1746-1746.	1.4	9
49	Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm?. Seminars in Radiation Oncology, 2011, 21, 196-202.	2.2	8
50	GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. Annals of Hematology, 2014, 93, 827-834.	1.8	8
51	Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. Scientific Reports, 2019, 9, 13544.	3.3	8
52	Prognostic indices in diffuse large Bâ€cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute Râ€CHOP 14 versus 21 phase 3 trial. British Journal of Haematology, 2021, 192, 1015-1019.	2.5	8
53	Evolution of eligibility criteria for diffuse large Bâ€eell lymphoma randomised controlled trials over 30Âyears. British Journal of Haematology, 2021, 193, 741-749.	2.5	8
54	Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). Blood, 2021, 138, 2493-2493.	1.4	8

#	Article	IF	CITATIONS
55	Caution in the Use of Immunohistochemistry for Determination of Cell of Origin in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2015, 33, 3215-3216.	1.6	7
56	Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study. BMJ Open, 2020, 10, e038312.	1.9	6
57	A consensus statement on the use of biosimilar medicines in hematology in Australia. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 211-221.	1.1	6
58	Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study. Blood, 2021, 138, 304-304.	1.4	6
59	Toxicity associated with high-dose intravenous methotrexate for hematological malignancies. Leukemia and Lymphoma, 2022, 63, 2375-2382.	1.3	6
60	Cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma undergoing standard chemotherapy: a longitudinal feasibility study. Supportive Care in Cancer, 0, , .	2.2	6
61	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplantâ€eligible patients with previously untreated mantle cell lymphoma. Hematological Oncology, 2019, 37, 253-260.	1.7	5
62	Urine cultures at the onset of febrile neutropenia rarely impact antibiotic management in asymptomatic adult cancer patients. Supportive Care in Cancer, 2019, 27, 1223-1227.	2.2	5
63	Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. Leukemia and Lymphoma, 2021, 62, 330-336.	1.3	5
64	Predicting primary treatment failure using interim FDGâ€PET scanning in diffuse large Bâ€cell lymphoma. European Journal of Haematology, 2021, 107, 475-483.	2.2	5
65	Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. Targeted Oncology, 2021, 16, 761-771.	3.6	5
66	The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial. Blood, 2021, 138, 45-45.	1.4	5
67	Rare Case of Precursor B-Cell Acute Lymphoblastic Leukemia Presenting As a Solitary Paraspinal Mass Alone. Journal of Clinical Oncology, 2013, 31, e383-e385.	1.6	4
68	Dalotuzumab in chemorefractory <i>KRAS</i> exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. International Journal of Cancer, 2017, 140, 431-439.	5.1	4
69	Limited utility of routine chest X-ray in initial evaluation of neutropenic fever in patients with haematological diseases undergoing chemotherapy. Internal Medicine Journal, 2018, 48, 556-560.	0.8	4
70	Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma. Cancer Chemotherapy and Pharmacology, 2020, 85, 133-140.	2.3	4
71	Use of Ultrasonography Facilitates Noninvasive Evaluation of Lymphadenopathy in a Lymph Node Diagnostic Clinic. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e179-e184.	0.4	4
72	Mycosis fungoides and Sézary syndrome: Australian clinical practice statement. Australasian Journal of Dermatology, 2021, 62, e8-e18.	0.7	4

#	Article	IF	CITATIONS
73	Flexible sigmoidoscopy—valuable in colorectal cancer. Nature Reviews Clinical Oncology, 2010, 7, 488-490.	27.6	3
74	Reply to M. Mohiuddin et al. Journal of Clinical Oncology, 2011, 29, 2737-2738.	1.6	3
75	CHOP VERSUS GEMâ€P IN THE FIRSTâ€LINE TREATMENT OF Tâ€CELL LYMPHOMA (PTCL): INITIAL RESULTS OF TH NRCI PHASE II RANDOMISED CHEMOâ€T TRIAL. Hematological Oncology, 2017, 35, 75-76.	IE UK 1.7	3
76	Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy, 2021, 38, 3789-3802.	2.9	3
77	R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial. Blood, 2015, 126, 2689-2689.	1.4	3
78	Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance. HemaSphere, 2021, 5, e648.	2.7	3
79	Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?. Lancet Oncology, The, 2010, 11, 1020-1021.	10.7	2
80	Diagnostic Medical Radiation Exposure in Surveillance of Aggressive Lymphoma: Clinical Trial Design Should Reflect Clinical Practice. Journal of Clinical Oncology, 2015, 33, 1219-1220.	1.6	2
81	Is Upfront Escalated BEACOPP for Advanced Hodgkin Lymphoma Becoming a Distant Memory?. Journal of Clinical Oncology, 2017, 35, 371-372.	1.6	2
82	Chemoimmunotherapy May Not Be Dead Yet in Chronic Lymphocytic Leukemia, But Fludarabine Plus Cyclophosphamide Plus Rituximab Is Potentially Facing Life Support. Journal of Clinical Oncology, 2017, 35, 4093-4094.	1.6	2
83	Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials. Oncology, 2019, 97, 270-276.	1.9	2
84	Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care. Lancet Haematology,the, 2019, 6, e119.	4.6	2
85	Caution in Expanding the Use of Abbreviated R-CHOP to Poor-Risk Limited-Stage DLBCL. Journal of Clinical Oncology, 2020, 38, 4221-4222.	1.6	2
86	Can PET eradicate irradiation in PMBCL?. Blood, 2020, 136, 2725-2726.	1.4	2
87	Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 226-233.	1.1	2
88	A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial. Blood, 2018, 132, 2956-2956.	1.4	2
89	AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2019, 134, 5332-5332.	1.4	2
90	The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative. Blood, 2019, 134, 3986-3986.	1.4	2

#	Article	IF	CITATIONS
91	Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial. Blood, 2014, 124, 1723-1723.	1.4	2
92	Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer. Clinical Colorectal Cancer, 2009, 8, 185-189.	2.3	1
93	Echocardiography has low utility in cancer patients with Staphylococcus aureus bacteraemia: findings from a retrospective study. Supportive Care in Cancer, 2018, 26, 3083-3089.	2.2	1
94	Routine Blood Tests in Asymptomatic Patients With Indolent Lymphoma Have Limited Ability to Detect Clinically Significant Disease Progression. JCO Oncology Practice, 2020, 16, e1315-e1323.	2.9	1
95	Exploration of motivation to participate in a study of cancer-related cognitive impairment among patients with newly diagnosed aggressive lymphoma: a qualitative sub-study. Supportive Care in Cancer, 2022, 30, 1331-1339.	2.2	1
96	Outcomes of Stage I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance. Blood, 2018, 132, 4148-4148.	1.4	1
97	Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 4094-4094.	1.4	1
98	Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013. Blood, 2014, 124, 1719-1719.	1.4	1
99	Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis. Blood, 2019, 134, 1620-1620.	1.4	1
100	Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. Blood, 2019, 134, 5328-5328.	1.4	1
101	Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 2021, , .	0.8	1
102	Metastatic breast cancer presenting as a primary hindgut neuroendocrine tumour. Anticancer Research, 2010, 30, 3015-8.	1.1	1
103	Inferior vena caval leiomyosarcoma in a patient with past bilateral retinoblastoma. Asia-Pacific Journal of Clinical Oncology, 2008, 4, 181-183.	1.1	0
104	ASPECCT: panitumumab versus cetuximab for colorectal cancer. Lancet Oncology, The, 2014, 15, e302-e303.	10.7	0
105	EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV-SPECIFIC CTL AND IBRUTINIB THERAPY. Hematological Oncology, 2019, 37, 130-132.	1.7	0
106	Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial. Blood, 2015, 126, 1516-1516.	1.4	0
107	Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012. Blood, 2015, 126, 1499-1499.	1.4	0
108	Patient Selection for High-Dose Methotrexate As Central Nervous System Prophylaxis in Diffuse Large B-Cell Lymphoma in Australia: Are We Getting It Right?. Blood, 2016, 128, 4217-4217.	1.4	0

#	Article	IF	CITATIONS
109	An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice. Blood, 2019, 134, 2849-2849.	1.4	0
110	Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance. Blood, 2020, 136, 36-38.	1.4	0